CSL Limited is an Australian-based manufacturer of medical products. Its products include various blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing.
Founded in 1916 the Commonwealth Serum Laboratories, an Australian government body focused on vaccine manufacture. The operation commenced plasma fractionation in 1952. It was privatised as CSL Ltd in 1994. In 2000 CSL doubled its size through the purchase of a Swiss plasma company, the Bern-based ZLB Bioplasma AG. In 2004, during a period of plasma oversupply, the company expanded again with the purchase of the German medical company Aventis Behring. The company was the 2nd Australian public comapny to have reached a share price of over $100 per share.
The company's headquarters remain in Parkville, Victoria, an inner suburb of Melbourne. CSL Behring is headquartered in King of Prussia, Pennsylvania and has manufacturing operations in the Swiss city of Berne, in Marburg in Germany, and Bradley, Illinois.
CSL is a public company whose stock is traded on the Australian Stock Exchange under the stock code CSL. The company completed an Initial Public Offering in June 1994 at A$2.30 per share. Today CSL stock is part of the S&P/ASX 50 Index.
CSL Limited's products can be separated by company division. Some of the key products produced by each division, circa 2006, include: